3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neuroendocrine Tumors
4
Pheochromocytoma
2
Paraganglioma
2
Vipoma
1
Neoplasms, Unknown Primary
1
Insulinoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastrinoma
1
Carcinoma, Merkel Cell
1
Carcinoid Tumor
1
Interventions
Gemcitabine
9
Carboplatin
8
Paclitaxel
6
Capecitabine
4
Bevacizumab
4
pembrolizumab
3
Irinotecan
3
Erlotinib Hydrochloride
3
atezolizumab
2
Peripheral Blood Stem Cell Transplantation
2
Oxaliplatin
2
Filgrastim
2
Cisplatin
2
CP protocol
2
tislelizumab
1
tegafur-gimeracil-oteracil
1
spartalizumab
1
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
etoposide phosphate
1
entrectinib
1
cobimetinib
1
belinostat
1
antineoplaston AS 2-1
1
antineoplaston A10
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Unknown Primary
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT04276597
2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2
Withdrawn